Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who completed the core study CACZ885H2251. A patient is defined as completing the core study if he/she completed the study up to and including the last visit (Visit 9).
Patients who have signed a written informed consent before any trial procedure is performed.
You may not be if
Patients for whom continuation in the extension 1 is not considered appropriate by the treating physician.
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive pregnancy test (serum or urine).
Female patients who were physiologically capable of becoming pregnant, unless they were:
* Female patients whose career, lifestyle, or sexual orientation precluded intercourse with a male partner.
* Female patients whose partners had been sterilized by vasectomy or other means.
* Using an acceptable method of contraception with a failure rate (Pearl Index (PI)) \< 1.
* Reliable contraception had to be maintained throughout the study and for 2 months after study drug discontinuation.
Clareo Health | Long Term Study of Canakinumab (ACZ885) in Patients With Gout
